Home > Insider Trading > Filing (0001883850-23-000109)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
872589	Regeneron Pharmaceuticals Inc.	REGN	Pharmaceutical Preparations (2834)	133444607

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1174475	S Michael Brown	777 Old Saw Mill River Road Tarrytown NY 10591		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2023-12-27	2,049	$482.68	3,296	No	4	M	Direct
Common Stock	Disposition	2023-12-27	2,049	$898.00	1,247	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Non-Qualified Stock Option (right to buy)	Disposition	2023-12-27	2,049	$0.00	2,049	$482.68

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0		2031-01-04	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	5,000	Indirect	by SLAT
Common Stock	6,162	Indirect	by Trust

Footnotes

Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 24, 2023.
These shares are held in a trust for the benefit of the reporting person's immediate family members. The reporting person's spouse is trustee of the trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that had passed from the date of grant became exercisable, and the remainder became exercisable on the first anniversary of the date of grant.